NuCana plc
corporate_fare Company Profile
NuCana plc (NASDAQ:NCNA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 8 items for NCNA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-13, rated 7/10. Across its 8 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for NCNA spans 6-K, 20-F, SCHEDULE 13D.
Recent high-impact activity:
- NuCana Q2 Loss Narrows to £3.1M; Cash Runway Extended into 2029
- Shareholders Approve Resolutions for Future Capital Raises
- NuCana Reports Q1 2026 Results, Secures FDA IND for NUC-7738, Extends Cash Runway into 2029
- NuCana plc Seeks Share Subdivision and Highly Dilutive Share Issuance Authority for Critical Financing
- NuCana plc Extends Cash Runway into 2029 via Significant Capital Raises and Reports Mixed Clinical Progress
Financial Snapshot
Short Interest & Short Volume
4.88 days to coverFINRA reported short interest of 139,251 shares in NCNA as of the October 30, 2026 settlement, a 4.0% decrease from the prior period — about 4.9 days to cover at its recent average daily volume. On November 20, 2026, 22.6% of NCNA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
NCNA files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.